News Liquidia Corporation

Equities

LQDA

US53635D2027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
12.55 ^USD	-3.09%		-9.45%	+4.32%

Apr. 01	Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	MT
Apr. 01	Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	AQ
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	Apr. 01	MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	Apr. 01	DJ
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder	Apr. 01	GL
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing	Mar. 20	MT
Liquidia Corporation(NasdaqCM:LQDA) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating	Mar. 14	MT
Transcript : Liquidia Corporation, 2023 Earnings Call, Mar 13, 2024	Mar. 13
Liquidia's 2023 Net Loss Widens, Revenue Increases -- Shares Advance Pre-Bell	Mar. 13	MT
Liquidia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update	Mar. 13	GL
Certain Stock Units of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	Mar. 11	CI
Certain Warrants of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	Mar. 11	CI
Certain Options of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	Mar. 11	CI
Certain Common Stock of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	Mar. 11	CI
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024	Mar. 06	GL
United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia	Feb. 21	MT
Spotlight On Upcoming Oral Arguments – February 2024	Feb. 13	AQ
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress	Jan. 30	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Liquidia Corporation

Equities

LQDA

US53635D2027

Summary

Filters